Teriparatide

An anabolic osteoporosis medicine with fracture-reduction data. Lifetime duration is limited on the label because of rodent osteosarcoma findings. Not a general 'healing peptide.'

Recombinant PTH fragment 1–34. Intermittent PTH signaling is anabolic to bone (osteoblast activity); continuous high PTH is catabolic — the distinction is why this is a pulsed daily injection, not a drip.

Fracture-prevention trials in postmenopausal osteoporosis and other high-risk groups. Head-to-heads with antiresorptives exist. Anabolic window and sequence with denosumab/bisphosphonates are specialty decisions.

FDA-approved for osteoporosis at high fracture risk. Prescription. Lifetime exposure caps apply.

Prescription Forteo or a licensed biosimilar, daily injection, from a pharmacy. Lifetime duration is limited on the label. Anabolic sequence with antiresorptives is a specialty decision.

Same four pathways as the Sourcing guide.

Covered for high-fracture-risk osteoporosis with prior auth, often after an oral bisphosphonate attempt. Duration caps and specialty-pharmacy rules apply. Not a cash 'healing peptide.'

PTH fragments sold as research chemicals are not Forteo. Bone anabolic drugs are a bad grey-market class: hypercalcemia is not theoretical.

Strand does not list vendors. See the grey market.

Hypercalcemia, orthostatic hypotension after injection, leg cramps. Boxed warning historically related to osteosarcoma in rats; label and duration limits have evolved — use current PI. Avoid in bone malignancy / unexplained ALP elevation.

• Hypercalcemia, orthostatic hypotension after injection, leg cramps.
• Avoid in bone malignancy or unexplained ALP elevation.
• Rodent osteosarcoma findings shaped duration limits — use the current label.

• Neer et al. · 2001 · N Engl J Med

  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal osteoporosis. PMID 11346808.

• Forteo label

  FDA prescribing information.